new-recommended-broker-banner new-recommended-broker-banner
Practice Stock Trading Your Capital Is At Risk

N4 Pharma (N4P) Share Price Rallies After Nuvec Patent Grant 

Updated: 1 Oct 2021

Shares of N4 Pharma (LON: N4P) are rallying Friday on news that the European Patent Office (EPO) has granted a European patent in relation to Nuvec.

The patent for Nuvec refers explicitly to its composition, particulate materials and methods for making the particulate materials.

The company said it is now validated in its main territories across Europe and adds to existing grants in Australia and Japan. 


In addition, N4 said it has been notified by the Chinese Patent Office (CPO) of its intention to grant a patent relating to Nuvec. 

Nigel Theobald, CEO of N4 Pharma, commented: “We are delighted that the EPO has now formally granted the European Patent which is now validated across Europe. 

“This achieves another key step in our IP strategy where we are also making excellent progress following the notice of allowance made recently by the CPO for the potentially huge market of China and the ongoing discussions in other key jurisdictions.”

N4 Pharma shares are up 9.12% at 8.68p so far on Friday, after reaching a high of 9.5p earlier in the session.

Should you invest in N4 Pharma shares?

N4 Pharma shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are N4P shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .